960 related articles for article (PubMed ID: 28833869)
21. Psychometric performance assessment of Malay and Malaysian English version of EQ-5D-5L in the Malaysian population.
Shafie AA; Vasan Thakumar A; Lim CJ; Luo N
Qual Life Res; 2019 Jan; 28(1):153-162. PubMed ID: 30317426
[TBL] [Abstract][Full Text] [Related]
22. The EQ-5D-5L Valuation study in Thailand.
Pattanaphesaj J; Thavorncharoensap M; Ramos-Goñi JM; Tongsiri S; Ingsrisawang L; Teerawattananon Y
Expert Rev Pharmacoecon Outcomes Res; 2018 Oct; 18(5):551-558. PubMed ID: 29958008
[TBL] [Abstract][Full Text] [Related]
23. Experience-Based Swedish TTO and VAS Value Sets for EQ-5D-5L Health States.
Burström K; Teni FS; Gerdtham UG; Leidl R; Helgesson G; Rolfson O; Henriksson M
Pharmacoeconomics; 2020 Aug; 38(8):839-856. PubMed ID: 32307663
[TBL] [Abstract][Full Text] [Related]
24. An EQ-5D-5L value set based on Uruguayan population preferences.
Augustovski F; Rey-Ares L; Irazola V; Garay OU; Gianneo O; Fernández G; Morales M; Gibbons L; Ramos-Goñi JM
Qual Life Res; 2016 Feb; 25(2):323-333. PubMed ID: 26242249
[TBL] [Abstract][Full Text] [Related]
25. Peruvian Valuation of the EQ-5D-5L: A Direct Comparison of Time Trade-Off and Discrete Choice Experiments.
Augustovski F; Belizán M; Gibbons L; Reyes N; Stolk E; Craig BM; Tejada RA
Value Health; 2020 Jul; 23(7):880-888. PubMed ID: 32762989
[TBL] [Abstract][Full Text] [Related]
26. German Value Set for the EQ-5D-5L.
Ludwig K; Graf von der Schulenburg JM; Greiner W
Pharmacoeconomics; 2018 Jun; 36(6):663-674. PubMed ID: 29460066
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Value Set Based on DCE and/or TTO Data: Scoring for EQ-5D-5L Health States in Japan.
Shiroiwa T; Ikeda S; Noto S; Igarashi A; Fukuda T; Saito S; Shimozuma K
Value Health; 2016; 19(5):648-54. PubMed ID: 27565282
[TBL] [Abstract][Full Text] [Related]
28. A new tool for creating personal and social EQ-5D-5L value sets, including valuing 'dead'.
Sullivan T; Hansen P; Ombler F; Derrett S; Devlin N
Soc Sci Med; 2020 Feb; 246():112707. PubMed ID: 31945596
[TBL] [Abstract][Full Text] [Related]
29. EQ-5D-5L: a value set for Romania.
Olariu E; Mohammed W; Oluboyede Y; Caplescu R; Niculescu-Aron IG; Paveliu MS; Vale L
Eur J Health Econ; 2023 Apr; 24(3):399-412. PubMed ID: 35688994
[TBL] [Abstract][Full Text] [Related]
30. Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.
McCaffrey N; Kaambwa B; Currow DC; Ratcliffe J
Health Qual Life Outcomes; 2016 Sep; 14(1):133. PubMed ID: 27644755
[TBL] [Abstract][Full Text] [Related]
31. Comparing the UK EQ-5D-3L and English EQ-5D-5L Value Sets.
Mulhern B; Feng Y; Shah K; Janssen MF; Herdman M; van Hout B; Devlin N
Pharmacoeconomics; 2018 Jun; 36(6):699-713. PubMed ID: 29476363
[TBL] [Abstract][Full Text] [Related]
32. A Comparison of PROPr and EQ-5D-5L Value Sets.
Pan T; Mulhern B; Viney R; Norman R; Hanmer J; Devlin N
Pharmacoeconomics; 2022 Mar; 40(3):297-307. PubMed ID: 34786591
[TBL] [Abstract][Full Text] [Related]
33. An EQ-5D-5L Value Set for Vietnam.
Mai VQ; Sun S; Minh HV; Luo N; Giang KB; Lindholm L; Sahlen KG
Qual Life Res; 2020 Jul; 29(7):1923-1933. PubMed ID: 32221805
[TBL] [Abstract][Full Text] [Related]
34. The EQ-5D-5L Value Set for England: Findings of a Quality Assurance Program.
Hernandez Alava M; Pudney S; Wailoo A
Value Health; 2020 May; 23(5):642-648. PubMed ID: 32389230
[TBL] [Abstract][Full Text] [Related]
35. Developing the EQ-5D-5L Value Set for Uganda Using the 'Lite' Protocol.
Yang F; Katumba KR; Roudijk B; Yang Z; Revill P; Griffin S; Ochanda PN; Lamorde M; Greco G; Seeley J; Sculpher M
Pharmacoeconomics; 2022 Mar; 40(3):309-321. PubMed ID: 34841471
[TBL] [Abstract][Full Text] [Related]
36. The EQ-5D-5L Is Superior to the -3L Version in Measuring Health-related Quality of Life in Patients Awaiting THA or TKA.
Jin X; Al Sayah F; Ohinmaa A; Marshall DA; Smith C; Johnson JA
Clin Orthop Relat Res; 2019 Jul; 477(7):1632-1644. PubMed ID: 30801280
[TBL] [Abstract][Full Text] [Related]
37. Head-to-Head Comparison of EQ-5D-3L and EQ-5D-5L Health Values.
Selivanova A; Buskens E; Krabbe PFM
Pharmacoeconomics; 2018 Jun; 36(6):715-725. PubMed ID: 29623559
[TBL] [Abstract][Full Text] [Related]
38. Valuation of the EQ-5D-3L in Russia.
Omelyanovskiy V; Musina N; Ratushnyak S; Bezdenezhnykh T; Fediaeva V; Roudijk B; Purba FD
Qual Life Res; 2021 Jul; 30(7):1997-2007. PubMed ID: 33713323
[TBL] [Abstract][Full Text] [Related]
39. Effect of Health State Sampling Methods on Model Predictions of EQ-5D-5L Values: Small Designs Can Suffice.
Yang Z; Luo N; Bonsel G; Busschbach J; Stolk E
Value Health; 2019 Jan; 22(1):38-44. PubMed ID: 30661632
[TBL] [Abstract][Full Text] [Related]
40. Head-to-head comparison between the EQ-5D-5L and the EQ-5D-3L in general population health surveys.
Martí-Pastor M; Pont A; Ávila M; Garin O; Vilagut G; Forero CG; Pardo Y; Tresserras R; Medina-Bustos A; Garcia-Codina O; Cabasés J; Rajmil L; Alonso J; Ferrer M
Popul Health Metr; 2018 Aug; 16(1):14. PubMed ID: 30115092
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
